Sibylle Loibl, MD, on HR+ HER2– Primary Breast Cancer: Palbociclib and Endocrine Therapy
Sibylle Loibl, MD, of the German Breast Group, discusses the first phase III results from the PENELOPE-B study of palbociclib combined with endocrine therapy in patients with hormone receptor–positive, HER2-negative primary breast cancer who are at high risk for relapse after neoadjuvant chemotherapy (Abstract GS1-02).